Chemistry:Relatlimab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Lymphocyte activation gene-3 (LAG-3) |
| Clinical data | |
| Other names | BMS-986016, relatlimab-rmbw |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6472H9922N1710O2024S38 |
| Molar mass | 145288.79 g·mol−1 |
Relatlimab is a monoclonal antibody designed for the treatment of melanoma.[3][4] It is used in combination with nivolumab to treat melanoma.[2][5]
Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor.[2][5] It is under development by Bristol-Myers Squibb.[2][5] It is made using Chinese hamster ovary cells.[2]
History
As of 2018[update], relatlimab is undergoing Phase II/III trials.[6]
The combination nivolumab/relatlimab (Opdualag) was approved for medical use in the United States in March 2022.[2][5]
Names
Relatlimab is the United States Adopted Name (USAN) and the international nonproprietary name (INN).[7][8][9]
References
- ↑ "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-12-22"]. 22 December 2023. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/multiple-additions-2023-12-22.html.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 "Opdualag- nivolumab and relatlimab-rmbw injection". 18 March 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b22c9d83-3256-4e17-85f7-f331a504adc6.
- ↑ Translational Medicine: Optimizing Preclinical Safety Evaluation of Biopharmaceuticals. Boca Raton, Florida: CRC Press. 2021. ISBN 978-1-00-047185-4.
- ↑ "LAG-3 and PD-1 blockade raises the bar for melanoma.". Nature Cancer 2 (12): 1251–3. December 2021. doi:10.1038/s43018-021-00276-8. PMID 35121906.
- ↑ 5.0 5.1 5.2 5.3 "U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma" (Press release). Bristol Myers Squibb. 18 March 2022. Retrieved 19 March 2022 – via Business Wire.
- ↑ Clinical trial number NCT03704077 for "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma" at ClinicalTrials.gov
- ↑ "Relatlimab". https://searchusan.ama-assn.org/finder/usan/search/RELATLIMAB/relevant/1/.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Relatlimab, American Medical Association.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information 33 (1). 2019.
 |  |
